Animalcare Group (ANCR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

291.00p
   
  • Change Today:
      11.00p
  • 52 Week High: 301.00p
  • 52 Week Low: 209.00p
  • Currency: UK Pounds
  • Shares Issued: 68.99m
  • Volume: 37,801
  • Market Cap: £200.76m
  • Beta: 0.02

Deal with Barclays    Trade now with Barclays Stockbrokers

Animalcare to gobble up Ecuphar

By Josh White

Date: Friday 23 Jun 2017

LONDON (ShareCast) - (ShareCast News) - Generic veterinary medicines and identification products and services supplier Animalcare Group announced on Friday that it had entered into a conditional share purchase agreement to acquire the entire issued share capital of Ecuphar.
The AIM-traded firm described Ecuphar as a European animal health company focused on the development and sale of veterinary pharmaceutical products that provide "significant benefits" to animal health in the companion animal, equine and production animal markets.

It said the consideration for the acquisition was structured on a consolidated Animalcare/Ecuphar enlarged issued share capital ratio of 37:63 - after taking into account dilution from certain Animalcare incentive arrangements - and would be satisfied through the issue of consideration shares and cash to the Ecuphar vendors.

The cash component of the consideration would be satisfied in part through a placing of approximately 8.6 million new placing shares - representing approximately 40.4% of the existing issued share capital - to raise gross proceeds of not less than £30.0m, with the balance of £4.0m to be funded by existing cash held by the group.

Animalcare said the number of consideration shares to be issued to the vendors of Ecuphar would be determined following completion of the placing, and by reference to the exact number of new placing shares issued in the placing.

The acquisition constitutes a reverse takeover for the purposes of Rule 14 of the AIM Rules for Companies and, as such, was conditional upon shareholder approval.

"We are very pleased to present to shareholders this highly complementary acquisition which will provide enhanced scale and capabilities for the group and create a pan-European animal health platform from which to accelerate growth," said Animalcare CEO Iain Menneer.

"The acquisition will be truly transformational: it will expand our direct sales operation to cover seven countries and our international reach into 50 export markets, as well as greatly increasing the depth and diversity of our licensed veterinary medicines product range.

"As an enlarged group we expect to deliver a growing, highly cash generative, dividend paying company with a solid pipeline of new products and multiple cross-selling opportunities."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

ANCR Market Data

Currency UK Pounds
Share Price 291.00p
Change Today 11.00p
% Change 3.93 %
52 Week High 301.00p
52 Week Low 209.00p
Volume 37,801
Shares Issued 68.99m
Market Cap £200.76m
Beta 0.02

ANCR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.01% below the market average94.01% below the market average94.01% below the market average94.01% below the market average94.01% below the market average
91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average
Price Trend
80.24% above the market average80.24% above the market average80.24% above the market average80.24% above the market average80.24% above the market average
86.96% above the sector average86.96% above the sector average86.96% above the sector average86.96% above the sector average86.96% above the sector average
Income
89.52% below the market average89.52% below the market average89.52% below the market average89.52% below the market average89.52% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
10.29% above the market average10.29% above the market average10.29% above the market average10.29% above the market average10.29% above the market average
18.75% below the sector average18.75% below the sector average18.75% below the sector average18.75% below the sector average18.75% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 4
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

ANCR Dividends

  Latest Previous
  Final Interim
Ex-Div 19-Jun-25 17-Oct-24
Paid 18-Jul-25 15-Nov-24
Amount 3.00p 2.00p

Trades for 18-Jul-2025

Time Volume / Share Price
14:38 11,631 @ 286.75p
15:49 3 @ 294.75p
15:37 250 @ 292.00p
15:34 1,750 @ 287.30p
15:25 1,000 @ 290.00p

ANCR Key Personnel

CFO Chris Brewster
CEO Jenny Winter

Top of Page